LEADER 01899nam  2200373   450 
001 9910688418103321
005 20230623121215.0
035   $a(CKB)5400000000040557
035   $a(NjHacI)995400000000040557
035   $a(EXLCZ)995400000000040557
100   $a20230623d2020      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAmyotrophic Lateral Sclerosis /$fedited by Muralidhar L. Hegde
210  1$aLondon, United Kingdom :$cIntechOpen,$d2020.
215   $a1 online resource (160 pages) $cillustrations
311   $a1-83880-582-6 
330   $aA flurry of recent research on the role of the RNA/DNA-binding proteins TDP-43 and FUS as well as a dozen other factors (e.g., C9ORF72 and profilin) has led to a new paradigm in our understanding of the pathobiology of the motor neuron disease, Amyotrophic Lateral Sclerosis (ALS). How these factors trigger neuromuscular dysfunction is critical for developing more effective ALS therapeutics. The 'gain-of-toxicity' or 'loss-of-function' of these etiological factors is a key question. Recent studies on the imbalance in genome damage versus repair have opened avenues for potential DNA repair-based therapeutics. This book highlights emerging science in the area of ALS and discusses key approaches and mechanisms essential for developing a cure for ALS.
517   $aAmyotrophic Lateral Sclerosis 
606   $aAmyotrophic lateral sclerosis
606   $aAmyotrophic lateral sclerosis$xTreatment
615  0$aAmyotrophic lateral sclerosis.
615  0$aAmyotrophic lateral sclerosis$xTreatment.
676   $a616.83
702   $aHegde$b Muralidhar L.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688418103321
996   $aAmyotrophic lateral sclerosis$92004420
997   $aUNINA